AbbVie (ABBV) Cash & Equivalents (2012 - 2026)

AbbVie has disclosed Cash & Equivalents across 15 years of filings, most recently posting $9.4 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 81.47% year-over-year to $9.4 billion; the TTM figure through Mar 2026 stood at $9.4 billion (up 81.47% YoY), while the FY2025 annual figure was $5.2 billion, down 5.34% from the prior year.
• Cash & Equivalents improved to $9.4 billion in Q1 2026, from $5.2 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for ABBV reached as high as $18.1 billion in Q1 2024 and fell as low as $5.2 billion in Q1 2025.
• The 5-year median for Cash & Equivalents is $8.5 billion (2022), against an average of $9.0 billion.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 169.21% — and 2025, when it tumbled 71.36%.
• A 5-year view of Cash & Equivalents shows it stood at $9.2 billion in 2022, then surged by 39.27% to $12.8 billion in 2023, then tumbled by 56.89% to $5.5 billion in 2024, then decreased by 5.34% to $5.2 billion in 2025, then soared by 79.59% to $9.4 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $9.4 billion, $5.2 billion, and $5.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.